Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy, a Leading Cause of Blindness WorldwideThe collaboration with CDR-Life is the second strategic partnership within a year for Boehringer Ingelheim in retinal diseases, furthering the company ’s commitment to develop novel treatments and technologies for patients who have only inadequate treatment options Together the partners will advance CDR-Life ’s preclinical antibody fragments targeting a key pathway in geographic atrophy (GA) 
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news